Key Takeaways:
Nuvalent Inc. secured a September 18, 2026, target action date from the US Food and Drug Administration for its lead cancer drug, zidesamtinib, setting up a potential commercial launch this year for the company.
"We are continuing to build our commercial infrastructure in preparation for a potential US launch of zidesamtinib in TKI pre-treated ROS1-positive NSCLC, if approved," James Porter, Chief Executive Officer of Nuvalent, said in a statement.
The New Drug Application for zidesamtinib covers its use in patients with advanced ROS1-positive non-small cell lung cancer (NSCLC) who have been previously treated with a tyrosine kinase inhibitor (TKI). Alongside the zidesamtinib review, Nuvalent also announced it has submitted a separate NDA to the FDA for neladalkib, an investigational therapy for TKI pre-treated ALK-positive NSCLC.
The zidesamtinib application is supported by data from the ARROS-1 clinical trial, which showed clinically meaningful activity, including in patients with the difficult-to-treat G2032R resistance mutation. The neladalkib submission was based on the ALKOVE-1 trial, which showed encouraging activity and intracranial responses in ALK-positive lung cancer. Nuvalent plans to present pivotal data from the ALKOVE-1 study at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting.
The dual regulatory milestones position Nuvalent for a potential transition from a clinical-stage to a commercial-stage company in 2026. Investors will now be focused on the September 18 PDUFA date as the next major catalyst, followed by the potential commercial launch of zidesamtinib.
This article is for informational purposes only and does not constitute investment advice.
